ScreenerHero

TNXP Tonix Pharmaceuticals Holding Corp.

NAS · US · Healthcare · Biotechnology · tonixpharma.com
7.550USD-1.88%Mkt Cap: 129.49M $P/E: —

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap129.49M USD
Enterprise Value-42.98M USD
Revenue (TTM)29.10M USD
Gross Profit6.47M USD
Net Income (TTM)-124.02M USD
Revenue/Share2.28 USD
Last Price7.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees142
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.98
PEG—
EV/EBITDA0.26
EV/Revenue-1.48
P/S4.53
P/B0.48
EPS (TTM)-13.06
EPS (Forward)-7.88
52W Range
7.4201% of range25.69
52W High25.69 USD
52W Low7.420 USD
Profitability
Gross Margin49.34%
Oper. Margin-314.05%
EBITDA Margin0.00%
Profit Margin-946.22%
ROE-50.59%
ROA-44.75%
Growth
Revenue Growth577.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-99.84M USD
CapEx (TTM)3.37M USD
FCF Margin-329.05%
FCF Yield-73.95%
Net Debt-174.96M USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.01
Current Ratio6.61
Quick Ratio6.12
Book Value/Sh15.99 USD
Cash/Share10.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 1, 2019
Splits
Last Split1:100
Split DateFeb 5, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.50 USD
Upside (mean)+489.4%
Target Range22.00 USD – 65.00 USD
22.00+489.4% to mean65.00
# Analysts4
Ownership
Shares Out.17.15M
Float14.12M
Insiders0.16%
Institutions55.98%
Short Interest
Short Ratio6.7d
Short % Float16.57%
Short % Out.16.55%
Shares Short2.84M
Short (prev mo.)3.41M
Technical
SMA 5011.62 (-35.0%)
SMA 20013.44 (-43.8%)
Beta1.79
S&P 52W Chg16.45%
Avg Vol (30d)547.50K
Avg Vol (10d)596.22K
Technical Indicators
RSI (14)18.5
MACD-1.0972
MACD Signal-0.7714
MACD Hist.-0.3258
BB Upper13.89 USD
BB Middle10.43 USD
BB Lower6.976 USD
BB Width66.26%
ATR (14)0.6411 USD
Vol Ratio (20d)1.19x